ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0098

CCL2 and CCR2 in Adult Onset Still’s Disease

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0295

CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0075

CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0155

Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0415

Characteristics of Arthritis in Adult IgA Vasculitis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0306

Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0020

Characteristics of Rheumatology Outpatients with Suspected or Confirmed COVID-19 During the Pandemic in New York City

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0176

Characterization and Molecular Mechanism Underlying NEMO Deleted Exon 5 Autoinflammatory Syndrome (NDAS)

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0044

Characterization of Racial Disparities in Rheumatoid Arthritis Treatment Choice and Location of Care

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0234

Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0072

Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0398

Chest CT Ordering Practices at Expert Scleroderma Centers in the United States

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0182

Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0083

Chronic Nonbacterial Osteomyelitis Is Associated with HLA-B*27

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0085

Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

«Previous Page
1
…
3
4
5
6
7
…
35
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].